362 related articles for article (PubMed ID: 23374736)
21. Primary Hyperparathyroidism: Effects on Bone Health.
Zanocco KA; Yeh MW
Endocrinol Metab Clin North Am; 2017 Mar; 46(1):87-104. PubMed ID: 28131138
[TBL] [Abstract][Full Text] [Related]
22. Primary hyperparathyroidism: Skeletal and non-skeletal effects, diagnosis and management.
Pyram R; Mahajan G; Gliwa A
Maturitas; 2011 Nov; 70(3):246-55. PubMed ID: 21943558
[TBL] [Abstract][Full Text] [Related]
23. An overview of normocalcemic primary hyperparathyroidism.
Pawlowska M; Cusano NE
Curr Opin Endocrinol Diabetes Obes; 2015 Dec; 22(6):413-21. PubMed ID: 26512768
[TBL] [Abstract][Full Text] [Related]
24. Primary hyperparathyroidism.
Bilezikian JP; Cusano NE; Khan AA; Liu JM; Marcocci C; Bandeira F
Nat Rev Dis Primers; 2016 May; 2():16033. PubMed ID: 27194212
[TBL] [Abstract][Full Text] [Related]
25. Classical and Nonclassical Manifestations of Primary Hyperparathyroidism.
El-Hajj Fuleihan G; Chakhtoura M; Cipriani C; Eastell R; Karonova T; Liu JM; Minisola S; Mithal A; Moreira CA; Peacock M; Schini M; Silva B; Walker M; El Zein O; Marcocci C
J Bone Miner Res; 2022 Nov; 37(11):2330-2350. PubMed ID: 36245249
[TBL] [Abstract][Full Text] [Related]
26. Primary hyperparathyroidism: Disease of diverse genetic, symptomatic, and biochemical phenotypes.
Medina JE; Randolph GW; Angelos P; Zafereo ME; Tufano RP; Kowalski LP; Montenegro FLM; Owen RP; Khafif A; Suárez C; Shaha AR; Rodrigo JP; Krempl GA; Rinaldo A; Silver CE; Ferlito A
Head Neck; 2021 Dec; 43(12):3996-4009. PubMed ID: 34541734
[TBL] [Abstract][Full Text] [Related]
27. [Osteitis fibrosa cystica as the initial manifestation of primary hyperparathyroidism].
Aragón Valera C; Carrasco de la Fuente M; Alpañés Buesa M; Sanchón Rodríguez R; Antón Bravo T; de la Calle Blasco H
Endocrinol Nutr; 2009 Mar; 56(3):140-2. PubMed ID: 19627728
[TBL] [Abstract][Full Text] [Related]
28. Influence of age and gender on presentation of symptomatic primary hyperparathyroidism.
Shah VN; Bhadada SK; Bhansali A; Behera A; Mittal BR; Bhavin V
J Postgrad Med; 2012; 58(2):107-11. PubMed ID: 22718053
[TBL] [Abstract][Full Text] [Related]
29. Serum calcium (S-Ca), the forgotten test: preliminary results of an appropriateness strategy to detect primary hyperparathyroidism (pHPT).
Salinas M; López-Garrigós M; Pomares F; Lugo J; Asencio A; López-Penabad L; Dominguez JR; Leiva-Salinas C
Bone; 2013 Sep; 56(1):73-6. PubMed ID: 23707628
[TBL] [Abstract][Full Text] [Related]
30. Evaluation and Management of Elevated Parathyroid Hormone Levels in Normocalcemic Patients.
Cusano NE
Med Clin North Am; 2021 Nov; 105(6):1135-1150. PubMed ID: 34688419
[TBL] [Abstract][Full Text] [Related]
31. The characteristics of clinical changes in primary hyperparathyroidism in Chinese patients.
Yao XA; Wei BJ; Jiang T; Chang H
J Bone Miner Metab; 2019 Mar; 37(2):336-341. PubMed ID: 29721808
[TBL] [Abstract][Full Text] [Related]
32. Characteristics, management, and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016.
Sun B; Guo B; Wu B; Kang J; Deng X; Zhang Z; Fan Y
Osteoporos Int; 2018 Mar; 29(3):635-642. PubMed ID: 29198075
[TBL] [Abstract][Full Text] [Related]
33. [Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].
Arranz Martín A; Azcárate Villalón A; Luque Ramírez M; Santana Durán B; Marazuela Azpíroz M; Paniagua Ruiz A; Carraro R; Gómez Pan A
Endocrinol Nutr; 2011 Jan; 58(1):24-31. PubMed ID: 21277266
[TBL] [Abstract][Full Text] [Related]
34. Radiologic Manifestation of Bone Involvement in Primary Hyperparathyroidism: Prevalence and Clinical Significance in a Southern European Series.
Castellano E; Attanasio R; Boriano A; Borretta V; Gennaro M; Latina A; Borretta G
Endocr Pract; 2020 Sep; 26(9):983-989. PubMed ID: 33471703
[TBL] [Abstract][Full Text] [Related]
35. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
Imanishi Y; Kawata T; Kenko T; Wada M; Nagano N; Miki T; Arnold A; Inaba M
Calcif Tissue Int; 2011 Jul; 89(1):29-35. PubMed ID: 21541686
[TBL] [Abstract][Full Text] [Related]
36. Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study.
Rejnmark L; Amstrup AK; Mollerup CL; Heickendorff L; Mosekilde L
J Clin Endocrinol Metab; 2013 Jan; 98(1):87-96. PubMed ID: 23150677
[TBL] [Abstract][Full Text] [Related]
37. Calcium/phosphate ratio: an additional tool for the clinical management of asymptomatic primary hyperparathyroidism?
Castellano E; Attanasio R; Boriano A; Gianotti L; Borretta G
J Endocrinol Invest; 2024 Jun; 47(6):1505-1511. PubMed ID: 38129742
[TBL] [Abstract][Full Text] [Related]
38. Cinacalcet for the treatment of primary hyperparathyroidism.
Dillon ML; Frazee LA
Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675
[TBL] [Abstract][Full Text] [Related]
39. Primary hyperparathyroidism and pancreatitis.
Misgar RA; Bhat MH; Rather TA; Masoodi SR; Wani AI; Bashir MI; Wani MA; Malik AA
J Endocrinol Invest; 2020 Oct; 43(10):1493-1498. PubMed ID: 32253728
[TBL] [Abstract][Full Text] [Related]
40. Transient hypercortisolism and symptomatic hyperthyroidism associated to primary hyperparathyroidism in an elderly patient: case report and literature review.
Sabbadin C; Donà G; Bordin L; Iacobone M; Camozzi V; Mian C; Armanini D
BMC Endocr Disord; 2015 Jan; 15():4. PubMed ID: 25631825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
